Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)58.05
  • Today's Change0.150 / 0.26%
  • Shares traded59.53k
  • 1 Year change-34.22%
  • Beta1.2097
Data delayed at least 15 minutes, as of Jul 04 2025 16:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

  • Revenue in CHF (TTM)605.26m
  • Net income in CHF120.25m
  • Incorporated1971
  • Employees2.21k
  • Location
    Bachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
  • Phone+41 619352333
  • Fax+41 619352324
  • Websitehttps://www.bachem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gubra A/S-12.54bn-12.54bn919.41m236.00------------------------------------------------29.63--18.03------
Kuros Biosciences AG68.24m-3.38m1.08bn122.00--20.70--15.87-0.0947-0.10882.341.360.96531.917.68559,379.90-4.78-10.85-5.94-12.2882.0484.11-4.95-31.801.69--0.0777--129.67101.5962.67--60.45--
BioArctic AB125.99m74.89m1.14bn116.0018.238.5113.459.0810.2010.2017.1621.850.931----14,180,610.0055.34-2.8760.55-3.2297.6186.5959.44-12.41----0.0257---58.22-1.80-177.24--52.19--
Evotec SE737.23m-193.59m1.20bn4.77k--1.40--1.62-1.17-1.174.445.140.379520.844.29163,293.80-9.97-2.40-12.34-2.8713.6221.49-26.26-6.781.93-2.030.3442--1.9912.29-133.67--32.89--
Galapagos NV276.33m-167.74m1.51bn704.00--0.5866--5.46-2.72-2.574.4841.700.07050.77345.59419,666.20-4.28-2.04-4.74-2.2884.42---60.70-27.567.86--0.0039--14.99-20.8267.85--12.44--
Genus plc728.12m-4.34m1.52bn3.44k--2.7235.622.09-0.0612-0.061210.167.820.6585--6.11195,289.30-0.62753.30-0.71993.87-----0.9534.981.33--0.365662.72-3.036.48-76.280.2551-2.682.93
BB BIOTECH AG69.17m-425.53m1.70bn86.00--0.8607--24.51-7.78-7.781.2635.550.029--5.61804,244.20-17.82-1.24-19.26-1.3594.8097.19-615.24-39.47--0.07710.00--21,076.79-31.20136.74-35.45---11.94
Zealand Pharma A/S6.98m-148.61m3.35bn385.00--3.19--480.37-17.30-17.300.811117.530.00880.54090.7554166,250.80-18.66-32.33-19.63-36.4993.3995.31-2,128.64-515.0325.07--0.0453---81.718.69-53.30---10.98--
BACHEM HOLDING AG605.26m120.25m4.35bn2.21k36.133.1326.637.191.611.618.0718.550.33571.072.91274,245.106.678.267.619.4430.1631.5519.8720.061.33--0.000252.544.8414.057.5017.2956.917.21
Qiagen NV1.59bn74.39m8.31bn5.70k119.093.0736.545.230.34480.34487.7513.360.35292.115.64294,973.101.655.761.916.8864.0964.314.6816.852.83--0.2924--0.65655.32-75.51---9.03--
Eurofins Scientific SE6.50bn593.45m10.37bn62.70k18.642.138.631.593.261.8135.7428.580.638438.445.00110,868.306.317.657.889.5322.3323.959.8811.411.097.950.401423.546.708.7822.8515.364.45--
Genmab A/S2.57bn900.65m10.42bn2.64k11.582.4510.854.06111.90111.90318.72529.570.543411.544.387,631,606.0019.0717.7021.1319.0795.12--35.1035.775.32--0.0263--30.5731.1680.1028.5021.52--
Data as of Jul 04 2025. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

11.70%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Mar 20251.99m2.65%
VV Verm�gensverwaltung AGas of 31 Mar 20251.16m1.55%
UBS Asset Management Switzerland AGas of 30 May 20251.15m1.53%
The Vanguard Group, Inc.as of 04 Jun 20251.11m1.49%
Capital Research & Management Co. (Global Investors)as of 31 Mar 2025773.91k1.03%
Norges Bank Investment Managementas of 31 Dec 2024771.61k1.03%
Z�rcher Kantonalbank (Investment Management)as of 30 Apr 2025600.24k0.80%
BlackRock Fund Advisorsas of 05 Jun 2025449.39k0.60%
Juno Investment Partnersas of 31 Mar 2025390.47k0.52%
GAM Investment Management (Switzerland) AGas of 28 Feb 2025379.06k0.51%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.